Upadacitinib is an oral Janus kinase (JAK) inhibitor developed by AbbVie for the treatment of several inflammatory and autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis. It was designed to selectively inhibit JAK1 to improve efficacy while reducing side effects associated with broader JAK inhibition. Upadacitinib was discovered in the early 2010s, progressed through clinical trials, and was first approved in 2019, after which it became an important option for patients needing advanced targeted anti-inflammatory therapy.
Image
